DNA methyltransferase 3b (DNMT3b), tumor tissue DNA methylation, Gleason score, and prostate cancer mortality: Investigating causal relationships

Cancer Causes and Control

Volumn 23, Issue 9, 2012, Pages 1549-1555

  Gillio Tos, Anna ^a   Fiano, Valentina ^a   Zugna, Daniela ^a   Vizzini, Loredana ^a   Pearce, Neil ^b,c   Delsedime, Luisa ^d   Merletti, Franco ^a,b   Richiardi, Lorenzo ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MASSEY UNIVERSITY   (New Zealand)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d MOLINETTE HOSPITAL   (Italy)

Author keywords

Causal relationship; DNA methylation; DNA methyltransferase 3b; Gleason score; Mortality; Prostate cancer

Indexed keywords

APC PROTEIN; DNA METHYLTRANSFERASE 3B; GLUTATHIONE TRANSFERASE P1; TRANSCRIPTION FACTOR RUNX3;

ALLELE; APC PROTEIN GENE; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; DNA METHYLATION; DNA METHYLTRANSFERASE 3B GENE; DNA SEQUENCE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; GLUTATHIONE TRANSFERASE P1 GENE; HAZARD RATIO; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION FACTOR RUNX3 GENE;

AGED; COHORT STUDIES; DISEASE PROGRESSION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; NEOPLASM GRADING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 84864874747     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-0032-9     Document Type: Article

References (32)

1. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 27:457-463
2. Esteller M (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16(Spec No 1):R50-R59
3. Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG (2004) Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 46:698-708
4. Park JY (2010) Promoter hypermethylation in prostate cancer. Cancer Control 17:245-255
5. Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, Akre O, Gillio-Tos A, Merletti F (2009) Promoter methylation in APC, RUNX3 and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 27:3161-3168
6. Jones PA, Liang G (2009) Rethinking how DNA methylation patterns are maintained. Nat Rev Gene 10:805-811
7. Ezzikouri S, El Feydi AE, Benazzouz M, Afifi R, El Kihal L, Hassar M, Akil A, Pineau P, Benjelloun S (2009) Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol 9:877-881
8. Jones JS, Amos CI, Pande M, Gu X, Chen J, Campos IM, Wei Q, Rodriguez-Bigas M, Lynch PM, Frazier ML (2006) DNMT3b polymorphism and hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomarkers Prev 15:886-891
9. Cebrian A, Pharoah PD, Ahmed S, Ropero S, Fraga MF, Smith PL, Conroy D, Luben R, Perkins B, Easton DF, Dunning AM, Esteller M, Ponder BA (2006) Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 27:1661-1669
10. Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q (2002) A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res 6:4992-4995
11. Lee SJ, Jeon HS, Jang JS, Park SH, Lee GY, Lee BH, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Cho YL, Jung TH, Park JY (2005) DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 26:403-409
12. Montgomery KG, Liu MC, Eccles DM, Campbell IG (2004) The DNMT3B C ? T promoter polymorphism and risk of breast cancer in a British population: a case-control study. Breast Cancer Res 6:R390-R394
13. Singal R, Das PM, Manoharan M, Reis IM, Schlesselman JJ (2005) Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep 14:569-573
14. Fan H, Zhang F, Hu J, Liu D, Zhao Z (2008) Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case-control study. J Exp Clin Cancer Res 27:24
15. de Vogel S, Wouters KA, Gottschalk RW, van Scooten FJ, de Goeij AF, de Bruine AP, Goldbohm RA, van den Brandt PA, Weijenberg MP, van Engeland M (2009) Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev 18:3086-3096
16. Feuer EJ, Merrill RM, Hankey BF (1999) Cancer surveillance series: interpreting trends in prostate cancer-part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91:1025-1032
17. Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk. JASA 94:496-509
18. Petersen M, Sinisi S, van der Laan M (2006) Estimation of direct causal effects. Epidemiology 17:276-284
19. Martin NE, Mucci LA, Loda M, Depinho RA (2011) Prognostic determinants in prostate cancer. Cancer J 17:429-437
20. Kulis M, Esteller M (2010) DNA methylation and cancer. Adv Genet 70:27-56
21. Kim H, Kwon YM, Kim JS, Han J, Shim YM, Park J, Kim DH (2006) Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary non small cell lung cancer. Cancer 107:1042-1049
22. Xing J, Stewart DJ, Gu J, Lu C, Spitz MR, Wu X (2008) Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer 98:1716-1722
23. Liu Z, Wang L, Wang LE, Sturgis EM, Wei Q (2008) Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 268:158-165
24. Wang L, Rodriguez M, Kim ES, Xu Y, Bekele N, El-Naggar AK, Hong WK, Mao L, Oh YW (2004) A novel C/T polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3B6 is associated with prognosis in head and neck cancer. Int J Oncol 25:993-999
25. Wu Y, Lin JS (2007) DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: a casecontrol study. World J Gastroenterol 13:6082-6086
26. Aung PP, Matsumura S, Kuraoka K, Kunimitsu K, Yoshida K, Matsusaki K, Nakayama H, Yasui W (2005) No evidence of correlation between the single nucleotide polymorphism of DNMT3B promoter and gastric cancer risk in a Japanese population. Oncol Rep 14:1151-1154
27. Kaufman JS, Maclehose RF, Kaufman S (2004) A further critique of the analytic strategy of adjusting for covariates to identify biologic mediation. Epidemiol Perspect Innov I:4
28. Troyer DA, Lucia MS, de Bruïne AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW (2009) Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev 18:2717-2722
29. Relton CL, Davey Smith G (2010) Epigenetic epidemiology of common complex disease: prospects for prediction, prevention, and treatment. PLoS Med 7:e1000356
30. Jurkowska RZ, Jurkowski TP, Jeltsch A (2011) Structure and function of mammalian DNA methyltransferases. ChemBioChem 12:206-222
31. Miremadi A, OestergaardMZ, Pharoah PD, CaldasC (2007) Cancer genetics of epigenetic genes. Hum Mol Genet 16(Spec No 1): R28-R49
32. Phé V, Cussenot O, Rouprět M (2010) Methylated genes as potential biomarkers in prostate cancer. BJU Int 105:1364-1370